Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Short Interest Update

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the recipient of a large drop in short interest in the month of August. As of August 15th, there was short interest totaling 52,200 shares, a drop of 25.3% from the July 31st total of 69,900 shares. Based on an average trading volume of 199,500 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 199,500 shares, the days-to-cover ratio is currently 0.3 days.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

Shares of SGIOY opened at $9.06 on Wednesday. The company has a market capitalization of $15.41 billion, a PE ratio of 15.55, a price-to-earnings-growth ratio of 2.06 and a beta of 0.20. Shionogi & Co., Ltd. Unsponsored ADR has a one year low of $6.53 and a one year high of $9.14. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.13. The company’s fifty day moving average price is $8.66 and its 200 day moving average price is $8.26.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its earnings results on Monday, July 28th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. The firm had revenue of $672.90 million during the quarter, compared to the consensus estimate of $719.55 million. As a group, analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.